Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002332 · ClinicalTrials.gov registry record · Phase 2
A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs
A Phase 2 study of HIV Infections, sponsored by Immunobiology Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT00002332: Completed Phase 2 study of HIV Infections, sponsored by Immunobiology Research Institute.
NCT00002332 is a Phase 2 study of HIV Infections that has completed, run by Immunobiology Research Institute. The registered enrollment target is 60 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002332, a Phase 2 study of HIV Infections, has completed, sponsored by Immunobiology Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
To evaluate the mechanism whereby thymopentin appears to retard the progressive immune suppression attributable to HIV infection.
Conditions Studied
Interventions
- DRUG Thymopentin
Study Locations (3)
California
- Dr Marcus Conant - San Francisco
- Dr Jeffrey Galpin - Tarzana
Pennsylvania
- Novum Inc - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Phase | Phase 2 |
What the finished NCT00002332 record still lists
NCT00002332 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Thymopentin is the first listed.
NCT00002332 reports a single indexed study location in California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00002332 about?
NCT00002332 is a clinical study titled "A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs". To evaluate the mechanism whereby thymopentin appears to retard the progressive immune suppression attributable to HIV infection.
What is the current status of trial NCT00002332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants.
What conditions does trial NCT00002332 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002332?
The interventions under investigation include: Thymopentin (DRUG).
Who is sponsoring clinical trial NCT00002332?
This trial is sponsored by Immunobiology Research Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002332 being conducted?
This trial has 3 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002332's enrollment target sits among peer trials
60 322nd of 542 higher than 205 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors